Block Organ Transplant Purchases from China Act of 2025
Key claim: The Block Act of 2025 would prohibit Medicare, Medicaid, and private insurers from covering organ transplants performed in China or using organs not procured through the U.S. OPTN, and would bar providers from performing such transplants except life-saving follow-up care.
Abstract
(HR2114 · 119th Congress) Block Organ Transplant Purchases from China Act of 2025 or the Block Act of 2025 This bill prohibits Medicare, Medicaid, and private health insurers from covering organ transplants that occur in China or that involve organs that are not procured through the U.S. Organ Procurement and Transplantation Network. The bill also prohibits health care providers from performing such a transplant or related services, except for life-saving services that are necessary as a result of such a transplant. Violations are subject to criminal and civil penalties. Latest action (2025-03-14): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
If enacted, this bill would carve out a new category of transplants that Medicare, Medicaid, and private insurers cannot cover—those performed in China or using organs outside the U.S. OPTN—and would criminalize provider participation in such procedures beyond life-saving follow-up. Patients seeking transplants abroad would face full out-of-pocket exposure, and U.S. transplant centers would face new compliance obligations tied to organ sourcing documentation.